Immunovant IMVT
NASDAQ IMVT
$28.36 -0.23 (-0.79%)
As of: Oct 21, 2026 · 3:59 PM EDT

Immunovant (IMVT) Operating Income (2019)

Updated

Immunovant's Operating Income came in at -$512,549 for fiscal Q2 2020 (quarter ended Sep 30, 2019).

Analysis

Immunovant (IMVT) Operating Income (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 11.75 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 7.14 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 6.43 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -584.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 4.75 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 3.16 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 3.51 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -10.39 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 4.27 Bn
10 Immunovant 5.85 Bn 2.63 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 -419,757.00
Jun 30, 2019 -92,342.00
API Access

Immunovant Operating Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-income&ticker=IMVT&period=max&api_key=YOUR_API_KEY